![NYX-2925 persistently enhances hippocampal structural plasticity and... | Download Scientific Diagram NYX-2925 persistently enhances hippocampal structural plasticity and... | Download Scientific Diagram](https://www.researchgate.net/publication/320888509/figure/fig4/AS:609730317807616@1522382444162/NYX-2925-persistently-enhances-hippocampal-structural-plasticity-and-metaplasticity.png)
NYX-2925 persistently enhances hippocampal structural plasticity and... | Download Scientific Diagram
![NYX-2925 Is a Novel N-Methyl-d-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain | Journal of Pharmacology and Experimental Therapeutics NYX-2925 Is a Novel N-Methyl-d-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain | Journal of Pharmacology and Experimental Therapeutics](https://jpet.aspetjournals.org/content/jpet/366/3/485/F5.large.jpg)
NYX-2925 Is a Novel N-Methyl-d-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain | Journal of Pharmacology and Experimental Therapeutics
NYX-2925 Is a Novel N-Methyl-d-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuro
![NYX-2925 persistently enhances hippocampal structural plasticity and... | Download Scientific Diagram NYX-2925 persistently enhances hippocampal structural plasticity and... | Download Scientific Diagram](https://www.researchgate.net/publication/320888509/figure/fig5/AS:609730317803521@1522382444237/NYX-2925-facilitates-learning-and-memory-by-activating-NMDA-receptors-A-NYX-2925_Q320.jpg)
NYX-2925 persistently enhances hippocampal structural plasticity and... | Download Scientific Diagram
![Negative Readouts: Updates on an NMDAR PAM, an MK2 inhibitor, and a Porcupine inhibitor - Drug Hunter Negative Readouts: Updates on an NMDAR PAM, an MK2 inhibitor, and a Porcupine inhibitor - Drug Hunter](https://drughunter.com/wp-content/uploads/2023/04/March-Negative-Readouts.png)
Negative Readouts: Updates on an NMDAR PAM, an MK2 inhibitor, and a Porcupine inhibitor - Drug Hunter
![Negative Readouts: Updates on an NMDAR PAM, an MK2 inhibitor, and a Porcupine inhibitor - Drug Hunter Negative Readouts: Updates on an NMDAR PAM, an MK2 inhibitor, and a Porcupine inhibitor - Drug Hunter](https://drughunter.com/wp-content/uploads/2023/04/Aptinyx-NMDAR-PAM_neg-readouts_fig-1024x260.png)
Negative Readouts: Updates on an NMDAR PAM, an MK2 inhibitor, and a Porcupine inhibitor - Drug Hunter
![Figure 1 from NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory | Semantic Scholar Figure 1 from NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/50890300d17df287da5f987a9ea60b06fcf9659f/3-Figure1-1.png)
Figure 1 from NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory | Semantic Scholar
![NYX-2925 Is a Novel N-Methyl-d-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain | Journal of Pharmacology and Experimental Therapeutics NYX-2925 Is a Novel N-Methyl-d-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain | Journal of Pharmacology and Experimental Therapeutics](https://jpet.aspetjournals.org/content/jpet/366/3/485/F4.large.jpg)
NYX-2925 Is a Novel N-Methyl-d-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain | Journal of Pharmacology and Experimental Therapeutics
NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Le
![Aptinyx stock slumps 34% as musculoskeletal pain drug NYX-2925 fails mid-stage study | Seeking Alpha Aptinyx stock slumps 34% as musculoskeletal pain drug NYX-2925 fails mid-stage study | Seeking Alpha](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1083262142/image_1083262142.jpg?io=getty-c-crop-16-9)
Aptinyx stock slumps 34% as musculoskeletal pain drug NYX-2925 fails mid-stage study | Seeking Alpha
![NYX‐2925 induces metabotropic N‐methyl‐d‐aspartate receptor (NMDAR) signaling that enhances synaptic NMDAR and α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor - Bowers - 2020 - Journal of Neurochemistry - Wiley Online Library NYX‐2925 induces metabotropic N‐methyl‐d‐aspartate receptor (NMDAR) signaling that enhances synaptic NMDAR and α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor - Bowers - 2020 - Journal of Neurochemistry - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/d5045005-8189-4800-8a79-022ffb68c34b/jnc14845-fig-0003-m.png)
NYX‐2925 induces metabotropic N‐methyl‐d‐aspartate receptor (NMDAR) signaling that enhances synaptic NMDAR and α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor - Bowers - 2020 - Journal of Neurochemistry - Wiley Online Library
Aptinyx Receives FDA Fast Track Designation for Development of NYX-2925 as Treatment for Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
![PDF] NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory | Semantic Scholar PDF] NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/50890300d17df287da5f987a9ea60b06fcf9659f/6-Figure2-1.png)
PDF] NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory | Semantic Scholar
![NYX-2925, A NOVEL, NON-OPIOID, SMALL-MOLECULE MODULATOR OF THE N-METHYL-d-ASPARTATE RECEPTOR (NMDAR), DEMONSTRATES POTENTIAL TO TREAT CHRONIC, SUPRASPINAL CENTRALIZED PAIN CONDITIONS - ScienceDirect NYX-2925, A NOVEL, NON-OPIOID, SMALL-MOLECULE MODULATOR OF THE N-METHYL-d-ASPARTATE RECEPTOR (NMDAR), DEMONSTRATES POTENTIAL TO TREAT CHRONIC, SUPRASPINAL CENTRALIZED PAIN CONDITIONS - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2590098620300543-gr2.jpg)
NYX-2925, A NOVEL, NON-OPIOID, SMALL-MOLECULE MODULATOR OF THE N-METHYL-d-ASPARTATE RECEPTOR (NMDAR), DEMONSTRATES POTENTIAL TO TREAT CHRONIC, SUPRASPINAL CENTRALIZED PAIN CONDITIONS - ScienceDirect
![The NMDAR modulator NYX-2925 alleviates neuropathic pain via a Src-dependent mechanism in the mPFC - ScienceDirect The NMDAR modulator NYX-2925 alleviates neuropathic pain via a Src-dependent mechanism in the mPFC - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2452073X19300145-gr1.jpg)